Cardiol Therapeutics Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Cardiol's ownership is fully public and diffuse, but the defining features for any owner are its pre-commercial status and its dependence on capital markets rather than any controlling stake. Its largest holders are the healthcare-focused funds Armistice Capital and Sabby Management, investors known for financing small, cash-consuming biotechs, alongside index funds, with no shareholder controlling the company. What owners hold is a clinical-stage biopharmaceutical company with no revenue, roughly 18 employees, and its value concentrated entirely in a drug pipeline. Cardiol is developing treatments for inflammatory heart disease: its lead candidate CardiolRx, an oral anti-inflammatory small molecule being studied in the MAVERIC pivotal trial for recurrent pericarditis and the ARCHER trial for acute myocarditis, and CRD-38, a subcutaneous anti-fibrotic therapy in earlier development. Because the company burns cash advancing these programs and has no product revenue, it funds itself through repeated equity issuance, which dilutes existing holders with each raise, a structural feature of its ownership. Shareholders are backing the probability-weighted value of Cardiol's clinical programs, particularly CardiolRx in pericarditis, a high-risk, binary bet whose value depends on clinical trial outcomes and continued access to funding. The equity's worth rests on whether these investigational medicines succeed in trials and reach approval, not on any current operations, making it a speculative claim on clinical outcomes managed by a small, capital-dependent company.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Cardiol has no revenue, because it has no approved product, and its equity is therefore a pure wager on clinical outcomes rather than an investment weighed on earnings. The company is developing treatments for inflammatory heart disease, and its promise lies in its clinical programs: CardiolRx, an oral anti-inflammatory small molecule, is being studied in the MAVERIC pivotal trial for recurrent pericarditis, a condition where a competitor's success has validated the market, and in the ARCHER trial for acute myocarditis, while CRD-38 offers an earlier-stage anti-fibrotic opportunity. Positive data could create substantial value in these cardiovascular indications. The countervailing risks are severe and characteristic of clinical-stage biotech: most drug candidates fail in trials, and pivotal studies like MAVERIC carry binary, make-or-break risk; the company has no revenue, burns cash, and depends on repeated equity raises that dilute holders and on continued access to capital markets; it is tiny, with roughly 18 employees; and even success would require competing against larger companies in cardiovascular disease. This is not an investment to be assessed on financial metrics but on the probability and magnitude of clinical success, a high-risk, binary proposition in which the outcome of the MAVERIC pericarditis trial and the company's ability to keep funding itself matter far more than any current figure, making Cardiol a speculative bet on inflammatory-heart-disease science whose value could rise sharply on positive data or collapse on failure.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| CardiolRx | Drug candidate | Oral anti-inflammatory small molecule |
| CRD-38 | Drug candidate | Subcutaneous anti-fibrotic therapy |
| MAVERIC | Clinical program | Recurrent pericarditis pivotal study |
| ARCHER | Clinical program | Acute myocarditis study |
Portfolio Analysis
Cardiol has no marketed products and therefore no commercial brands; its identity resides entirely in a small pipeline of investigational cardiovascular therapies and the clinical programs testing them. The lead candidate, CardiolRx, is an oral anti-inflammatory small molecule aimed at inflammatory heart conditions, being evaluated in the MAVERIC pivotal study for recurrent pericarditis, an inflammatory disease of the sac surrounding the heart, and in the ARCHER study for acute myocarditis, inflammation of the heart muscle, while CRD-38, a subcutaneous anti-fibrotic therapy, targets cardiac fibrosis in earlier development. The strategy is to develop differentiated anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases with significant unmet need, focusing on inflammatory heart conditions where existing treatment options are limited. What stands in for competitive strength here is the potential of the science and the clinical programs: the possibility that CardiolRx proves effective in pericarditis or myocarditis, indications where a validated market and unmet need exist. But these are potential assets, not realized ones, entirely dependent on clinical data. Cardiol's identity is that of a focused clinical-stage developer of cardiovascular anti-inflammatory therapies, and whatever competitive position it might achieve depends wholly on its investigational medicines succeeding in trials, a promise of scientific value that only positive pivotal data, above all from the MAVERIC study, could convert into a genuine, durable therapeutic franchise.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Cardiol Therapeutics ★ | N/A | $0 FY2025 | Clinical-stage cardiovascular therapeutics developer |
| Kiniksa Pharmaceuticals | N/A | $500M FY2025 | Commercial and clinical immunology company with pericarditis exposure |
| Rocket Pharmaceuticals | N/A | $0 FY2025 | Clinical-stage genetic medicines company |
| MyoKardia | N/A | Acquired | Cardiovascular drug-development precedent owned by Bristol Myers Squibb |
| AstraZeneca | N/A | $58B FY2025 | Global biopharmaceutical company with cardiovascular products |
Competitive Analysis
Cardiol competes, in effect, on the promise of its science, entering cardiovascular drug development as a tiny clinical-stage company against far larger and better-resourced rivals. In recurrent pericarditis, its lead indication, it faces Kiniksa Pharmaceuticals, a commercial and clinical company with an established pericarditis treatment that both validates the market and sets a competitive benchmark, while the broader cardiovascular field includes global pharmaceutical companies like AstraZeneca and the precedent of cardiovascular developers like MyoKardia, acquired by Bristol Myers Squibb. Against such competitors Cardiol has no marketed products, minimal resources, roughly 18 employees, and a pipeline that must still prove itself, so its only credible path is scientific differentiation: CardiolRx must demonstrate compelling efficacy and safety in pericarditis or myocarditis to carve out a position. The hazards dominate: entrenched or better-funded competitors, the high failure rate of clinical development, dependence on dilutive equity funding, and the reality that even a successful drug must compete against established or emerging alternatives. Cardiol competes as a hopeful, pre-commercial developer betting on differentiated cardiovascular anti-inflammatory science, and whether it can establish any defensible competitive position depends entirely on its clinical data, particularly the MAVERIC pericarditis results, proving its candidates against a validated competitor and the broader resources of the cardiovascular pharmaceutical industry, an outcome that remains, for now, unproven and uncertain.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| No material corporate acquisitions | N/A | 2017-2026 | Pipeline growth has been internally developed and licensed |
Acquisitions Analysis
Cardiol has completed no material acquisitions, and that absence reflects its nature as a small, internally focused clinical-stage developer. The company has built its value through intellectual property, drug formulation work, regulatory development and clinical trials rather than through corporate combinations, advancing its CardiolRx and CRD-38 candidates from its own research and licensing rather than by buying other companies. Its structural changes have come not from mergers but from financing: equity issuance has been the main source of both funding and ownership change, as the company repeatedly raises capital to fund its cash-consuming clinical programs, expanding its share count and diluting existing holders in the process. For a tiny, pre-revenue biotech, this reliance on internal development and equity funding rather than acquisitions is typical and appropriate, keeping the company focused on advancing its pipeline within its limited resources. Value creation, or its loss, therefore depends entirely on clinical execution, whether CardiolRx and CRD-38 succeed in their trials, not on dealmaking. The relevant corporate activity is not acquisition but capital raising, and Cardiol's future hinges on the outcomes of its clinical programs and its continued ability to fund them through equity markets, a small developer whose worth will be determined in the clinic rather than through any acquisition strategy, with its repeated financings the practical mechanism sustaining its development.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Cardiol's corporate structure reflects an independent clinical-stage company shaped by financings rather than by mergers or acquisitions. Founded in 2017 in Ontario, the company advanced CardiolRx into clinical development, completed a Toronto Stock Exchange initial public offering in 2019, and added a Nasdaq listing through American depositary shares in 2021 to broaden access to United States investors, remaining an independent developer throughout. It has not completed a material merger or corporate acquisition; its value has been built through intellectual property, formulation and regulatory work, and clinical trials, and its structural changes have come from equity issuance rather than combinations. Repeated capital raises, the main structural source of both funding and ownership change, have expanded the share count and diluted holders as the company funds its cash-consuming programs. The resulting structure is a small, dual-listed, independent clinical-stage biopharmaceutical company focused on inflammatory heart disease, organized into its pericarditis, myocarditis and fibrosis programs and its clinical operations. That structural simplicity, an independent developer funded by equity rather than reshaped by mergers, is appropriate for a pre-revenue biotech, and Cardiol's structural future depends not on corporate combination but on the outcomes of its clinical programs and its continued access to funding, with its dual Nasdaq and Toronto listing providing the capital-markets access on which its equity-funded development depends.
Ownership History
Ownership History Analysis
Cardiol's history is that of a small, independent biotech advancing a cardiovascular pipeline through clinical development on equity funding. Founded in 2017 in Ontario, the company brought its lead candidate CardiolRx into clinical development in 2018, completed a Toronto Stock Exchange initial public offering in 2019, and added a Nasdaq listing in 2021 to broaden United States investor access. Over the following years it concentrated its programs on inflammatory heart disease, generating data from the ARCHER myocarditis study in 2024 that supported continued development and advancing the MAVERIC pivotal study in recurrent pericarditis, which made CardiolRx its central late-stage asset by 2025. Throughout, the company has funded its cash-consuming clinical work through repeated equity raises that extended its runway while diluting prior holders, most recently in 2026. Generating no revenue with roughly 18 employees, Cardiol is a pre-commercial clinical-stage developer. Its history is that of a focused biotech that has methodically advanced its cardiovascular anti-inflammatory candidates through trials while repeatedly financing itself in the equity markets, and whose ultimate worth still awaits the verdict of its clinical programs, above all the MAVERIC pericarditis study, a company whose story remains unwritten because its investigational medicines have yet to prove themselves and whose survival depends on both clinical success and continued capital-markets access.
Ownership Explained
Cardiol Therapeutics is a clinical-stage biopharmaceutical company developing treatments for inflammatory heart disease, based in Oakville, Ontario and dual-listed on Nasdaq and the Toronto Stock Exchange as CRDL. Ownership is entirely public, with no controlling shareholder; its largest holders are the healthcare-focused funds Armistice Capital and Sabby Management alongside index funds. The company is tiny and pre-commercial, employing roughly 18 people and generating no revenue, since its lead candidate CardiolRx and its subcutaneous anti-fibrotic CRD-38 remain investigational. Its value rests on clinical programs, the MAVERIC pivotal study in recurrent pericarditis and the ARCHER study in acute myocarditis, and its progress has been funded through repeated equity raises that dilute existing holders.
A Cardiol share is a claim on a portfolio of clinical bets rather than an operating business, and its ownership reflects that reality. With no revenue, roughly 18 employees, and its medicines still in trials, the company burns cash and funds itself by issuing new equity, so ownership carries persistent dilution as each capital raise expands the share count. The presence of healthcare-focused funds like Armistice and Sabby, known for financing small biotechs, underscores the company's dependence on capital markets. What public holders are really backing is the probability-weighted value of Cardiol's clinical programs, above all CardiolRx in recurrent pericarditis, a high-risk, binary proposition whose payoff depends on clinical success and continued access to funding rather than on any current financial performance.